Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Apr 2;13(7):e032785.
doi: 10.1161/JAHA.123.032785. Epub 2024 Mar 27.

Risk of Death and Cardiovascular Events in Asian Patients With Atrial Fibrillation and Chronic Obstructive Pulmonary Disease: A Report From the Prospective APHRS Registry

Collaborators, Affiliations
Observational Study

Risk of Death and Cardiovascular Events in Asian Patients With Atrial Fibrillation and Chronic Obstructive Pulmonary Disease: A Report From the Prospective APHRS Registry

Tommaso Bucci et al. J Am Heart Assoc. .

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of adverse events in patients with atrial fibrillation (AF); however, few data are available on this topic in Asian populations.

Methods and results: Prospective observational study conducted on patients with AF enrolled in the Asia-Pacific Heart Rhythm Society (APHRS) AF Registry. The diagnosis of COPD was based on data reported in the case report form by the investigators. Cox-regression models were used to assess the 1-year risk of a primary composite outcome of all-cause death, thromboembolic events, acute coronary syndrome, and heart failure. Analysis on single outcomes and cardiovascular death was also performed. Interaction analysis was used to assess the risk of composite outcome and all-cause death in different subgroups. The study included 4094 patients with AF (mean±SD age 68.5±12 years, 34.6% female), of whom 112 (2.7%) had COPD. Patients with COPD showed a higher incidence of the primary composite outcome (25.1% versus 6.3%, P<0.001), all-cause death (14.9% versus 2.6%, P<0.001), cardiovascular death (2.0% versus 0.6%, P<0.001), and heart failure (8.3% versus 6.0%, P<0.001). On multiple Cox-regression analysis, COPD was associated with a higher risk of the primary composite outcome (hazard ratio [HR], 3.17 [95% CI, 2.05-4.90]), all-cause death (HR, 3.59 [95% CI, 2.04-6.30]), and heart failure (HR, 3.32 [95% CI, 1.56-7.03]); no statistically significant differences were found for other outcomes. The association between COPD and mortality was significantly modified by the use of beta blockers (Pint=0.018).

Conclusions: In Asian patients with AF, COPD is associated with worse prognosis. In patients with AF and COPD, the use of beta blockers was associated with a lower mortality.

Registration information: clinicaltrials.gov Identifier: NCT04807049.

Keywords: COPD; all‐cause death; atrial fibrillation; beta blockers; heart failure.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Univariable and multivariable logistic regression analyses for beta blocker and oral anticoagulation prescription in patients with chronic pulmonary obstructive disease.
*Multivariable logistic regression analysis adjusted for age ≥75 years, female sex, paroxysmal atrial fibrillation, hypertension, coronary artery disease, heart failure, diabetes, dyslipidemia, smoking habits, previous stroke/transient ischemic attack, peripheral artery disease, chronic kidney disease, cancer, dementia, European Heart Rhythm Association score, and previous bleeding. COPD indicates chronic obstructive pulmonary disease; and OAC, oral anticoagulation.
Figure 2
Figure 2. Kaplan–Meier curve for the risk of composite outcome in patients with atrial fibrillation and chronic obstructive pulmonary disease.
Thick lines represent survival probability, and thin lines represent 95% CIs. AF indicates atrial fibrillation; and COPD, chronic obstructive pulmonary disease.
Figure 3
Figure 3. Risk of composite outcome (A) and all‐cause death (B) in patients with chronic obstructive pulmonary disease according to different subgroups.
AF indicates atrial fibrillation; CKD, chronic kidney disease; and OAC, oral anticoagulation.

References

    1. Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, Gillum RF, Kim YH, McAnulty JH Jr, Zheng ZJ, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–847. doi: 10.1161/CIRCULATIONAHA.113.005119 - DOI - PMC - PubMed
    1. Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, et al. Cause of death and predictors of all‐cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5:e002197. doi: 10.1161/JAHA.115.002197 - DOI - PMC - PubMed
    1. Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, Ivanes F, Babuty D, Lip GY. Causes of death and influencing factors in patients with atrial fibrillation. Am J Med. 2016;129:1278–1287. doi: 10.1016/j.amjmed.2016.06.045 - DOI - PubMed
    1. Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, Boriani G, Harari S, Lip GYH, Proietti M, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta‐analysis of 4,200,000 patients. Eur Heart J. 2021;42:3541–3554. doi: 10.1093/eurheartj/ehab453 - DOI - PubMed
    1. Raparelli V, Pastori D, Pignataro SF, Vestri AR, Pignatelli P, Cangemi R, Proietti M, Davi G, Hiatt WR, Lip GYH, et al. Major adverse cardiovascular events in non‐valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Intern Emerg Med. 2018;13:651–660. doi: 10.1007/s11739-018-1835-9 - DOI - PubMed

Publication types

MeSH terms

Substances

Associated data